New York State Common Retirement Fund Sells 2,900 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

New York State Common Retirement Fund lessened its position in REGENXBIO Inc. (NASDAQ:RGNX) by 17.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,746 shares of the biotechnology company’s stock after selling 2,900 shares during the quarter. New York State Common Retirement Fund’s holdings in REGENXBIO were worth $106,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in RGNX. FMR LLC grew its stake in shares of REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,656 shares during the last quarter. GAMMA Investing LLC boosted its holdings in REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 2,510 shares during the period. Sigma Planning Corp grew its position in REGENXBIO by 17.5% in the 3rd quarter. Sigma Planning Corp now owns 38,210 shares of the biotechnology company’s stock valued at $401,000 after acquiring an additional 5,701 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in REGENXBIO by 48.5% in the third quarter. Harbor Capital Advisors Inc. now owns 36,082 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 11,784 shares during the period. Finally, Erste Asset Management GmbH purchased a new stake in REGENXBIO in the third quarter worth $140,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on RGNX. The Goldman Sachs Group cut shares of REGENXBIO from a “buy” rating to a “neutral” rating and cut their price target for the stock from $38.00 to $14.00 in a report on Tuesday, February 11th. Morgan Stanley reissued an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a research report on Friday, November 15th. Chardan Capital reaffirmed a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. Raymond James assumed coverage on shares of REGENXBIO in a research note on Friday, February 7th. They set an “outperform” rating and a $27.00 price target for the company. Finally, StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, REGENXBIO has a consensus rating of “Moderate Buy” and an average price target of $34.70.

REGENXBIO Trading Up 5.6 %

Shares of RGNX opened at $6.25 on Thursday. The firm has a market cap of $309.66 million, a PE ratio of -1.24 and a beta of 1.29. REGENXBIO Inc. has a 12 month low of $5.62 and a 12 month high of $27.16. The stock has a fifty day moving average price of $7.51 and a 200-day moving average price of $9.32.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.